（文章来源：证券日报） 证券日报网讯 12月26日，金城医药发布公告称，金城医药第六届董事会第十九次会议审议通过《关于 聘任公司高级管理人员及董事会秘书的议案》等。 ...

每经AI快讯，金城医药（SZ 300233，收盘价：14.29元）12月26日晚间发布公告称，公司第六届第十九 次董事会会议于2025年12月26日在公司会议室以现场和通讯相结合的方式召开。会议审议了《关于补选 公司第六届董事会董事长的议案》等文件。 每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 2024年1至12月份，金城医药的营业收入构成为：医药制造业占比100.0%。 （记者 曾健辉） 截至发稿，金城医药市值为55亿元。 ...

第六届董事会第十九次会议决议公告 证券代码：300233 证券简称：金城医药 公告编号：2025-083 山东金城医药集团股份有限公司 3、审议通过《关于聘任公司高级管理人员及董事会秘书的议案》 表决结果：8 票同意，0 票反对，0 票弃权。 本议案已经公司第六届董事会提名委员会第三次会议资格审查通过。具体内容 详见公司同日在巨潮资讯网披露的《关于补选董事长及董事会专门委员会委员、聘 任公司高级管理人员及董事会秘书的公告》。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十九次 会议通知于 2025 年 12 月 24 日以邮件通知方式发出。本次董事会会议于 2025 年 12 月 26 日在公司会议室以现场和通讯相结合的方式召开。会议应出席董事 8 名， 实际出席会议董事 8 名，其中独立董事王新宇、蔡启孝、李福利以通讯方式出席本 次会议。本次会议由副董事长李家全先生主持，公司部分高级管理人员列席。会议 的召开和表决程序符合《中华人民共和国公司法》和《公司章程》的有关规定 ...

山东金城医药集团股份有限公司 证券代码：300233 证券简称：金城医药 公告编号：2025-084 公司董事会于近日收到朱晓刚先生的书面辞职报告。朱晓刚先生因公司岗位调整 辞去公司董事会秘书、副总裁职务，其辞职后仍在公司任职。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号 —创业板上市公司规范运作》等法律法规和《公司章程》的有关规定，朱晓刚先生的 辞职报告自送达公司董事会之日起生效。朱晓刚先生原定任期至公司第六届董事会届 满之日止。截至本公告披露日，朱晓刚先生持有公司股份 324,000 股，其离任后将继 续遵守《上市公司股东减持股份管理暂行办法》《上市公司董事和高级管理人员所持 本公司股份及其变动管理规则》等股份减持的相关规定。 关于补选董事长及董事会专门委员会委员、聘任公司高级 管理人员及董事会秘书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日召 开第六届董事会第十九次会议，审议通过《关于补选公司第六届董事会董事长的议案》 《关于补 ...

证券日报网讯12月24日，金城医药（300233）在互动平台回答投资者提问时表示，公司在定期报告中披 露前十大股东情况，具体还请关注公司披露的定期报告。 ...

证券日报网讯 12月24日，金城医药在互动平台回答投资者提问时表示，截至2025年12月20日公司股东 总户数为27549户。 （文章来源：证券日报） ...

Core Viewpoint - The investigation into Jincheng Pharmaceutical's actual controller, Zhao Yeqing, concluded with his resignation on the same day the China Securities Regulatory Commission (CSRC) issued an administrative penalty for stock manipulation from 2017 to 2020 [1][2]. Summary by Relevant Sections Investigation and Penalty - Zhao Yeqing, the chairman and actual controller of Jincheng Pharmaceutical, was fined 1.5 million yuan and banned from the market for four years due to stock manipulation [2][8]. - The CSRC found that Zhao Yeqing, along with Wang Zhen and Liu Feng, manipulated the company's stock using 104 accounts over nearly 600 trading days, resulting in a loss of over 7.39 million yuan [4][8]. Manipulation Details - The manipulation involved a network of accounts that held an average of 18.58 million shares, representing 5.68% of the company's circulating shares, with a peak holding of 32.09 million shares, or 9.04% [6]. - During the manipulation period, the account group exhibited strong buying intentions, accounting for 17.29% of the market's buy orders and 23.02% of the market's trading volume, leading to a stock price increase of 21.30% compared to a 2.90% rise in the ChiNext Index [6][7]. Consequences and Company Response - The total trading volume during the manipulation was approximately 2.134 billion yuan for buying and 1.870 billion yuan for selling, culminating in a net loss of 739,200 yuan [8]. - Zhao Yeqing's resignation was announced on the same day as the penalty, and he will no longer hold any position within the company, although the administrative penalty only pertains to him personally and does not affect the company [9][10].

Core Viewpoint - Zhao Yeqing, the actual controller and chairman of Jincheng Pharmaceutical, was fined 1.5 million yuan by the Securities Regulatory Commission for manipulating the company's stock and received a four-year market ban [1] Group 1: Company Actions and Consequences - Zhao Yeqing resigned from his positions as chairman, director, and committee member of the board due to personal reasons on the same day he was penalized [1] - The manipulation led to a loss of 7.39 million yuan for Zhao, raising questions about how a chairman could incur losses while having insider information [1][3] - Zhao's stock manipulation occurred from August 18, 2017, to February 10, 2020, during a period when the stock market was generally declining, with the Shanghai Composite Index dropping from 3268.72 to 2890.49, a decrease of 11.57% [3] Group 2: Performance and Market Conditions - Jincheng Pharmaceutical's financial performance did not support Zhao's stock manipulation efforts, with revenue growth declining significantly in 2018 and 2019, and a notable drop in net profit [4] - The company's revenue in 2017 grew by 96.29%, but by 2019, revenue had decreased by 7.09%, and net profit attributable to shareholders fell by 74.25% [4] - Zhao's highest shareholding was only 9.04% of the circulating stock, which is below the typical control threshold of 30% needed to effectively manipulate stock prices [5] Group 3: Implications for Investors - The incident highlights the lack of profitability in the A-share market, as even a chairman with significant advantages lost money, indicating challenges for ordinary investors [3] - Zhao's actions serve as a cautionary tale for corporate leaders, emphasizing the importance of ethical conduct and the potential consequences of illegal activities [5]

证券日报网讯12月18日，金城医药（300233）在互动平台回答投资者提问时表示，12月20日以后公司方 能查询股东人数情况。 ...

格隆汇12月18日丨金城医药(300233.SZ)在投资者互动平台表示，公司具有大麻二酚中间体的技术能 力。 ...